Bond Barclay PLC 3% ( US06741RGE53 ) in USD

Issuer Barclay PLC
Market price 100 %  ▲ 
Country  United Kingdom
ISIN code  US06741RGE53 ( in USD )
Interest rate 3% per year ( payment 2 times a year)
Maturity 28/03/2025 - Bond has expired



Prospectus brochure of the bond Barclays PLC US06741RGE53 in USD 3%, expired


Minimal amount 1 000 USD
Total amount 595 000 USD
Cusip 06741RGE5
Standard & Poor's ( S&P ) rating A ( Upper medium grade - Investment-grade )
Moody's rating A1 ( Upper medium grade - Investment-grade )
Detailed description Barclays PLC is a British multinational banking and financial services corporation headquartered in London, offering a wide range of services including personal and corporate banking, investment banking, and wealth management.

The Bond issued by Barclay PLC ( United Kingdom ) , in USD, with the ISIN code US06741RGE53, pays a coupon of 3% per year.
The coupons are paid 2 times per year and the Bond maturity is 28/03/2025

The Bond issued by Barclay PLC ( United Kingdom ) , in USD, with the ISIN code US06741RGE53, was rated A1 ( Upper medium grade - Investment-grade ) by Moody's credit rating agency.

The Bond issued by Barclay PLC ( United Kingdom ) , in USD, with the ISIN code US06741RGE53, was rated A ( Upper medium grade - Investment-grade ) by Standard & Poor's ( S&P ) credit rating agency.







http://www.sec.gov/Archives/edgar/data/312070/000110465913024815/...
424B2 1 a13-6709_48424b2.htm 424B2 - 3 00RETAIL 12Y ( NON-CALLABLE)

CALCULATION OF REGISTRATION FEE

Title of Each Class of Securities Offered
Maximum Aggregate Offering Price
Amount of Registration Fee(1)







Global Medium-Term Notes, Series A
$595,000
$81.16



(1)
Calculated in accordance with Rule 457(r) of the Securities Act of 1933.


1 of 17
3/27/2013 3:00 PM


http://www.sec.gov/Archives/edgar/data/312070/000110465913024815/...

Pricing Supplement dated March 25, 2013
(To Prospectus dated August 31, 2010 and
Filed Pursuant to Rule 424(b)(2)
the Prospectus Supplement dated May 27, 2011)
Registration No. 333-169119










US$595,000
3.00% FIXED RATE NOTES DUE MARCH 28, 2025

Principal Amount:
US$595,000
Issuer:
Barclays Bank PLC

Issue Price:
100%
Series:
Global Medium-Term Notes, Series A

Original Issue Date:
March 28, 2013
Return at Maturity:
If you hold the Notes to maturity, you wil receive at least 100% of
your principal, subject to the creditworthiness of Barclays Bank
PLC. The Notes are not, either directly or indirectly, an
obligation of any third party, and any payment to be made on the
Notes, including any principal protection provided at maturity,
depends on the ability of Barclays Bank PLC to satisfy its
obligations as they come due.

Interest Rate Type:
Fixed Rate
Original Trade Date:
March 25, 2013

Maturity Date:
March 28, 2025
CUSIP:
06741RGE5
ISIN:
US06741RGE53
Denominations:
Minimum denominations of US$1,000 and
Business Day:
x
New York

integral multiples of US$1,000 thereafter.
x
London

o
Euro

o
Other (_________________)


Interest Rate:
3.00% per annum

Interest Payment Dates:
o Monthly, o Quarterly, x Semi-Annual y, o Annual y,

payable in arrears on the 28
th day of each March and September, commencing on September 28, 2013 and ending on the Maturity Date or the
relevant Survivor's Option Payment Date, if applicable.

Interest Period:
The initial Interest Period wil begin on, and include, the Original Issue Date and end on, but exclude, the first Interest Payment Date. Each
subsequent Interest Period wil begin on, and include, the Interest Payment Date for the immediately preceding Interest Period and end on, but
exclude, the next fol owing Interest Payment Date. The final Interest Period wil end on, but exclude, the Maturity Date (or the Survivor's Option
Payment Date, if applicable).

Survivor's Option:
Upon request by the authorized representative of the beneficial owner of the Notes, we wil repay those Notes prior to the Maturity Date following the
death of the beneficial owner of the Notes, provided such Notes were acquired by the deceased beneficial owner at least six months prior to the date
of the request.
The right to exercise this option wil be subject to:
·
limitations on the aggregate dollar amount of exercises by all holders of the Notes offered by this pricing supplement in any calendar

year; and
·
a maximum permitted dollar amount of an individual exercise with respect to the Notes offered by this pricing supplement by a holder of

the Notes offered by this pricing supplement in any calendar year.
For additional details regarding the Survivor's Option, see "Risk Factors -- Any Exercise of the Survivor's Option May Be Limited in Amount and Any
Repayments Made With Respect To a Survivor's Option Wil Not Be Made Immediately" and "Description of Survivor's Option" below.

Business Day Convention:
Fol owing, Unadjusted
Day Count Convention:
30/360

Settlement:
DTC; Book-entry; Transferable.

Listing:
The Notes wil not be listed on any U.S. securities exchange or quotation system.



Price to Public
Agent's Commission (1)
Proceeds to Barclays Bank PLC
Per Note
100%
1.45%
98.55%
Total
$595,000
$8,627.50
$586,372.50

(1) Barclays Capital Inc. will receive commissions from the Issuer equal to 1.45% of the principal amount of the notes, or $14.50 per $1,000 principal amount, and may retain all or a portion of these
commissions or use all or a portion of these commissions to pay selling concessions or fees to other dealers.

The Notes wil not be listed on any U.S. securities exchange or quotation system. Neither the Securities and Exchange Commission nor any state securities commission has approved or
disapproved of these securities or determined that this pricing supplement is truthful or complete. Any representation to the contrary is a criminal offense.

We may use this pricing supplement in the initial sale of Notes. In addition, Barclays Capital Inc. or another of our affiliates may use this pricing supplement in market resale transactions in any
Notes after their initial sale. Unless we or our agent informs you otherwise in the confirmation of sale, this pricing supplement is being used in a market resale transaction.

Any payment on the Notes is subject to the creditworthiness of the Issuer and is not guaranteed by any third party. For a description of risks with respect to the ability of Barclays Bank PLC
to satisfy its obligations as they come due, see "Issuer Credit Risk" in this pricing supplement.

Investing in the Notes involves a number of risks. See "Risk Factors" beginning on page S-6 of the prospectus supplement and "Selected Risk Factors" below.

The Notes constitute our direct, unconditional, unsecured and unsubordinated obligations and are not deposit liabilities of Barclays Bank PLC and are not insured by the
U.S. Federal Deposit Insurance Corporation or any other governmental agency of the United States, the United Kingdom or any other jurisdiction.

2 of 17
3/27/2013 3:00 PM


http://www.sec.gov/Archives/edgar/data/312070/000110465913024815/...


We urge you to consult your investment, legal, tax, accounting and other advisers and to invest in the Notes only after you and your
advisors have carefully considered the suitability of an investment in the Notes in light of your particular circumstances.

Barclays Bank PLC has filed a registration statement (including a prospectus) with the SEC for the offering to which this pricing supplement
relates. Before you invest, you should read the prospectus dated August 31, 2010, the prospectus supplement dated May 27, 2011, and
other documents Barclays Bank PLC has filed with the SEC for more complete information about Barclays Bank PLC. and this offering.
Buyers should rely upon this pricing supplement, the prospectus, the prospectus supplement, and any relevant free writing prospectus for
complete details. You may get these documents and other documents Barclays Bank PLC has filed for free by visiting EDGAR on the SEC
website at www.sec.gov, and you may also access the prospectus and prospectus supplement through the links below:

·
Prospectus dated August 31, 2010:


http://www.sec.gov/Archives/edgar/data/312070/000119312510201448/df3asr.htm

·
Prospectus Supplement dated May 27, 2011:


http://www.sec.gov/Archives/edgar/data/312070/000119312511152766/d424b3.htm

Our Central Index Key, or CIK, on the SEC website is 0000312070.

Alternatively, Barclays Capital Inc. or any agent or dealer participating in this offering will arrange to send you this pricing supplement, the
prospectus, the prospectus supplement and any relevant free writing prospectus if you request it by calling your Barclays Capital Inc. sales
representative, such dealer or 1-888-227-2275 (Extension 2-3430). A copy of the prospectus may be obtained from Barclays Capital Inc.,
745 Seventh Avenue--Attn: US InvSol Support, New York, NY 10019.

We reserve the right to change the terms of, or reject any offer to purchase the Notes prior to their issuance. In the event of any changes to the terms
of the Notes, we wil notify you and you wil be asked to accept such changes in connection with your purchase. You may also choose to reject such
changes in which case we may reject your offer to purchase.

As used in this term sheet, the "Company," "we," "us," or "our" refers to Barclays Bank PLC.

3 of 17
3/27/2013 3:00 PM


http://www.sec.gov/Archives/edgar/data/312070/000110465913024815/...

SELECTED RISK FACTORS

An investment in the Notes involves significant risks. You should read the risks summarized below in connection with, and the risks
summarized below are qualified by reference to, the risks described in more detail in the "Risk Factors" section beginning on page S-6 of
the prospectus supplement. We urge you to consult your investment, legal, tax, accounting and other advisers and to invest in the Notes
only after you and your advisors have carefully considered the suitability of an investment in the Notes in light of your particular
circumstances.

·
Issuer Credit Risk-- The Notes are our unsecured debt obligations, and are not, either directly or indirectly, an obligation of any third party.

Any payment to be made on the Notes, including any principal protection provided at maturity, depends on our ability to satisfy our obligations
as they come due. As a result, the actual and perceived creditworthiness of Barclays Bank PLC may affect the market value of the Notes and,
in the event we were to default on our obligations, you may not receive the principal protection or any other amounts owed to you under the
terms of the Notes.

·
Certain Built-In Costs Are Likely to Adversely Affect the Value of the Notes Prior to Maturity--While the payment at maturity described

in this pricing supplement is based on the ful principal amount of your Notes, the original issue price of the Notes includes the agent's
commission and the cost of hedging our obligations under the Notes through one or more of our affiliates. As a result, the price, if any, at which
Barclays Capital Inc. and other affiliates of Barclays Bank PLC wil be wil ing to purchase Notes from you in secondary market transactions wil
likely be lower than the price you paid for your Notes, and any sale prior to the Maturity Date could result in a substantial loss to you.

·
Potential Conflicts--We and our affiliates play a variety of roles in connection with the issuance of the Notes, including hedging our

obligations under the Notes. In performing these duties, the economic interests of our affiliates of ours are potential y adverse to your interests
as an investor in the Notes.

In addition, Barclays Wealth, the wealth management division of Barclays Capital Inc., may arrange for the sale of the Notes to certain of its
clients. In doing so, Barclays Wealth wil be acting as agent for Barclays Bank PLC and may receive compensation from Barclays Bank PLC in
the form of discounts and commissions. The role of Barclays Wealth as a provider of certain services to such customers and as agent for
Barclays Bank PLC in connection with the distribution of the Notes to investors may create a potential conflict of interest, which may be adverse
to such clients. Barclays Wealth is not acting as your agent or investment adviser, and is not representing you in any capacity with respect to
any purchase of Notes by you. Barclays Wealth is acting solely as agent for Barclays Bank PLC. If you are considering whether to invest in
the Notes through Barclays Wealth, we strongly urge you to seek independent financial and investment advice to assess the merits of such
investment.

·
Lack of Liquidity--The Notes wil not be listed on any securities exchange. Barclays Capital Inc. and other affiliates of Barclays Bank PLC

intend to make a secondary market for the Notes but are not required to do so, and may discontinue any such secondary market making at any
time, without notice. Barclays Capital Inc. may at any time hold unsold inventory, which may inhibit the development of a secondary market for
the Notes. Even if there is a secondary market, it may not provide enough liquidity to al ow you to trade or sel the Notes easily. Because other
dealers are not likely to make a secondary market for the Notes, the price at which you may be able to trade your Notes is likely to depend on
the price, if any, at which Barclays Capital Inc. and other affiliates of Barclays Bank PLC are wil ing to buy the Notes. The Notes are not
designed to be short-term trading instruments. Accordingly, you should be able and wil ing to hold your Notes to maturity.

·
Any Exercise of the Survivor's Option May Be Limited in Amount and Any Repayments Made With Respect to a Survivor's Option

Will Not Be Made Immediately -- The Survivor's Option is a provision of the Notes pursuant to which we agree to repay the Notes, if
requested by an authorized representative of the beneficial owner of the Notes, fol owing the death of the beneficial owner of the Notes,
provided that the Notes were acquired by the beneficial owner at least six months prior to the date of the request. Acceptance of an exercise of
a Survivor's Option and determinations regarding the eligibility and validity of any exercise of a Survivor's Option wil be at our sole discretion.
We also have the discretionary right to apply a limit set to the aggregate principal amount of Notes as to which exercises of the Survivor's
Option wil be accepted by us from al authorized representatives of deceased beneficial owners of Notes offered by this pricing supplement in
any calendar year to an amount equal to 2% of the aggregate principal amount of Notes offered by this pricing supplement outstanding as of
the end of the most recent calendar year. In addition, we have the discretionary

PS-1
4 of 17
3/27/2013 3:00 PM


http://www.sec.gov/Archives/edgar/data/312070/000110465913024815/...

right to limit to $250,000 the aggregate principal amount of Notes offered by this pricing supplement as to which exercises of the Survivor's
Option wil be accepted by us from the authorized representative of any deceased beneficial owner of the Notes offered by this pricing
supplement in any calendar year. Accordingly, no assurance can be given that the valid exercise of a Survivor's Option, if any, for a desired
amount wil be permitted in any single calendar year. In addition, as a result of the foregoing limitations, in some cases exercises of a Survivor's
Option may not result in any payment in the year that the Survivor's Option has been exercised, or in one or more years subsequent to the year
that the Survivor's Option was first exercised. Furthermore, Survivor's Option claims that were subject to the foregoing limitations in one or
more preceding year wil be deemed to be tendered in a succeeding calendar year (subject to the satisfaction of the conditions specified below,
including the submission of a Survivor's Option Reaffirmation Form (as defined below)) and in such succeeding calendar year wil again be
subject to the limitations described above. As a result, additional Survivor's Option exercises made in any such succeeding calendar year are
more likely to be limited by the limitations described above because the resubmission of the Survivor's Option exercises that were subject to
the limitations in preceding years may result in the limitation thresholds described above being reached earlier in succeeding calendar years.
These limitations and our discretion in applying any such limitations are discussed in more detail under the "Description of the Survivor's Option"
below.

If a valid request to exercise the Survivor's Option is not ful y accepted in any calendar year due to the application of any of the limitations
described in the preceding paragraph and in "Description of the Survivor's Option" below, the Notes wil be deemed to be tendered in the
fol owing calendar year only if an authorized representative of the deceased beneficial owner and any Financial Institution (as defined below)
through which the beneficial ownership interest in the Notes is held by the deceased beneficial owner reaffirms the exercise of the Survivor's
Option by submitting a Survivor's Option Reaffirmation Form (as defined below). If a completed Survivor's Option Reaffirmation Form is not
submitted to the trustee within 10 business days fol owing the delivery thereof by the trustee to the relevant Financial Institution through which
the beneficial ownership interest in the Notes is held by the deceased beneficial owner, the election to exercise the Survivor's Option wil be
deemed to have been withdrawn. The requirements relating to Survivor's Option Reaffirmation Forms are described in more detail under the
heading "Description of the Survivor's Option" below.

In addition, even if the Notes accepted for repayment pursuant to the valid exercise of a Survivor's Option in a certain calendar year, you wil
not receive immediate repayment. Repayment on Notes so accepted wil only be made on the first of two Survivor's Option Payment Dates
(either May 15 or November 15) that occurs 30 or more calendar days after the date of acceptance.

Whether you should exercise a Survivor's Option if you meet the eligibility requirements to do so is a decision you wil need to make in
consultation with your investment, legal, accounting, tax and other advisers, after considering al the facts and circumstances of your situation.
An additional consideration that you may wish to take into account is the prevailing secondary market prices for the notes, if any, at the time
you are considering the exercise of the Survivor's Option or the submission of a Survivor's Option Reaffirmation Form. In some circumstances,
such secondary market prices, if any, may be greater than the price you would receive upon the exercise of your Survivor's Option.
Accordingly, you should contact your advisers to determine the prevailing secondary market prices of the Notes, if any, in order to determine
whether to sel the notes to a market participant at such secondary market prices, if any, or to exercise the Survivor's Option to receive
repayment at a price equal to 100% of the principal amount plus accrued and unpaid interest.

For additional details regarding the Survivor's Option, see "Description of the Survivor's Option" in this pricing supplement.

·
Many Economic and Market Factors Will Impact the Value of the Notes--The value of the Notes wil be affected by a number of economic

and market factors that may either offset or magnify each other, including:

o the time to maturity of the Notes;
o interest and yield rates in the market generally;
o a variety of economic, financial, political, regulatory or judicial events; and
o our creditworthiness, including actual or anticipated downgrades in our credit ratings.

PS-2
5 of 17
3/27/2013 3:00 PM


http://www.sec.gov/Archives/edgar/data/312070/000110465913024815/...

DESCRIPTION OF SURVIVOR'S OPTION

Upon request by the authorized representative of the beneficial owner of the Notes, Barclays Bank PLC wil repay those Notes prior to the Maturity
Date fol owing the death of the beneficial owner of the Notes (the "Survivor's Option"), provided such Notes were acquired by the deceased beneficial
owner at least six months prior to the date of the request. Upon the valid exercise of the Survivor's Option and the proper tender of the Notes for
repayment, Barclays Bank PLC, subject to the limitations described below, wil repay such Notes, in whole or in part, at a price equal to 100% of the
principal amount of the deceased beneficial owner's beneficial interest in the Notes plus accrued and unpaid interest to the date of repayment. For
purposes of this section, a beneficial owner of Notes is a person who has the right, immediately prior to such person's death, to receive the proceeds
from the disposition of such Notes, as wel as the right to receive payment of the principal of the Notes.

To be valid, the Survivor's Option must be exercised by or on behalf of the person who has authority to act on behalf of the deceased beneficial owner
of the Notes under the laws of the applicable jurisdiction (including, without limitation, the personal representative of or the executor of the estate of the
deceased beneficial owner or the surviving joint owner with the deceased beneficial owner) (for purposes of this section, the authorized representative
of a deceased beneficial owner shall be referred to as an "Authorized Representative").

The death of a person holding a beneficial ownership interest in the Notes: (1) with any person in a joint tenancy with right of survivorship; or (2) with his
or her spouse in tenancy by the entirety, tenancy in common, as community property or in any other joint ownership arrangement, wil be deemed the
death of a beneficial owner of those Notes, and the entire principal amount of the Notes (subject to the limitations described below) held in this manner
wil be subject to repayment by Barclays Bank PLC upon request. However, the death of a person holding a beneficial ownership interest in Notes as
tenant in common with a person other than his or her spouse wil be deemed the death of a beneficial owner only with respect to such deceased
person's interest in the Notes, and only the deceased beneficial owner's percentage interest in the principal amount of the Notes wil be subject to
repayment.

If the ownership interest in the Notes is held by a nominee for a beneficial owner or by a custodian under a Uniform Gifts to Minors Act or Uniform
Transfer to Minors Act, or by a trustee of a trust, or by a guardian or committee for a beneficial owner, the death of the beneficial owner of the Notes
wil constitute death of the beneficial owner for purposes of the Survivor's Option, if the beneficial ownership interest can be established to the
satisfaction of Barclays Bank PLC. In these cases, the death of the nominee, custodian, trustee, guardian or committee wil not be deemed the death of
the beneficial owner of the Notes for purposes of the Survivor's Option.

Notes beneficially owned by a trust wil be regarded as beneficially owned by each beneficiary of the trust to the extent of that beneficiary's interest in
the trust (however, a trust's beneficiaries col ectively cannot be beneficial owners of more Notes than are owned by the trust); provided that the
beneficiary has a current interest in the trust, which may be evidenced by a current right to receive distributions or other proceeds from the trust. The
death of a beneficiary of a trust wil be deemed the death of the beneficial owner of the Notes beneficially owned by the trust to the extent of that
beneficiary's interest in the trust; however, only the death of al such individuals who are tenants by the entirety or joint tenants in a tenancy which is the
beneficiary of a trust wil be deemed the death of the beneficiary of the trust. The death of an individual who was a tenant in common in a tenancy which
is the beneficiary of a trust wil be deemed the death of the beneficiary of the trust only with respect to the deceased holder's beneficial ownership
interest in the Notes, unless spouses are the tenants in common, in which case only the death of both spouses wil be deemed the death of the
beneficiary of the trust.

Barclays Bank PLC has the discretionary right to limit the aggregate principal amount of the Notes as to which exercises of the Survivor's Option wil be
accepted by it from al authorized representatives of deceased beneficial owners of Notes offered by this pricing supplement in any calendar year, to an
amount equal to 2.0% of the aggregate amount of the Notes offered by this pricing supplement, outstanding as of the end of the most recent calendar
year ("Aggregate Put Limitation").

Barclays Bank PLC also has the discretionary right to limit to $250,000 the aggregate principal amount of Notes offered pursuant to this pricing
supplement as to which exercises of the Survivor's Option wil be accepted by Barclays Bank PLC from the Authorized Representative for any individual
deceased beneficial owner of such Notes in any calendar year ("Individual Put Limitation", and together with the "Aggregate Put Limitation", the "Put
Limitations").

In addition, the exercise of the Survivor's Option (a) for a principal amount of less than $1,000 or (b) if such exercise would result in a Note with a
principal amount of less than $1,000 outstanding, wil not be permitted. If, however, the original principal amount of such Notes was less than $1,000,
the Authorized Representative may exercise the Survivor's Option, but only for the ful principal amount of such Note.

PS-3
6 of 17
3/27/2013 3:00 PM


http://www.sec.gov/Archives/edgar/data/312070/000110465913024815/...

The application of the Put Limitations is at the sole and absolute discretion of Barclays Bank PLC. We may establish internal policies and procedures
for the application of the Put Limitations and may change any such policies and procedures from time to time, all in our sole discretion. We may also
elect in our sole discretion to waive the Put Limitations with respect to some beneficial owners without extending that waiver to other similarly situated
beneficial owners.

Except as described below, any Notes (or portion thereof) tendered pursuant to a valid exercise of the Survivor's Option may not be withdrawn.
Tenders of Notes (or portions thereof) pursuant to valid exercises of the Survivor's Option wil be accepted in the order in which such Notes are
received by the trustee, except for any Notes (or portion thereof) the acceptance of which would contravene any of the Put Limitations. Any Notes (or
portion thereof) accepted for repayment pursuant to exercise of the Survivor's Option wil be repaid on the first Survivor's Option Payment Date that
occurs 30 or more calendar days after the date of the acceptance. A "Survivor's Option Payment Date" means May 15 and November 15 of each
calendar year. For example, if the acceptance date of Notes tendered pursuant to a valid exercise of the Survivor's Option is May 10, 2013, we would
repay, subject to the Put Limitations, such Notes (or portion thereof) on the Survivor's Option Payment Date occurring on November 15, 2013, because
the May 15, 2013 Survivor's Option Payment Date would occur less than 30 days from the date of acceptance. If the Notes (or any portion thereof)
tendered for repayment pursuant to a valid exercise of the Survivor's Option (including through a Survivor's Option Reaffirmation Form (as described
below)) is not accepted, the trustee wil deliver a notice by first-class mail to the Authorized Representative at the address set forth in the Survivor's
Option Documentation, that states the reason such Notes (or portion thereof) has not been accepted for repayment. The procedures for obtaining
payment on valid exercise of the Survivor's Option that are not accepted as a result of the Put Limitations are described below.

If a Note tendered through a valid exercise of the Survivor's Option (including through a Survivor's Option Reaffirmation Form (as defined below) is not
accepted by Barclays Bank PLC, the trustee, upon receipt of a valid written instruction from Barclays Bank PLC or its agent, wil deliver a notice to the
registered holder that states the reason that Note has not been accepted for repayment.

To obtain repayment of the Notes pursuant to exercise of the Survivor's Option), an Authorized Representative and the broker or other entity through
which the beneficial interest in the Notes is held by the deceased beneficial owner (the "Financial Institution") must complete the Survivor's Option form
of notice ("Form of Notice"), which is attached hereto as Appendix A, and the Authorized Representative must provide to the Financial Institution the
fol owing items (col ectively, the "Survivor's Option Documentation"):

· a completed Form of Notice, using the form attached hereto as Appendix A, including the certifications that:

(a) the deceased was the beneficial owner of the Notes at the time of death and his or her interest in the note was acquired by the deceased
beneficial owner at least six months prior to the date of the request;

(b) the death of such beneficial owner has occurred and the date of such death;

(c) the Authorized Representative has authority to act on behalf of the deceased beneficial owner and has requested repayment of the Notes;

(d) the Financial Institution currently holds such Notes as a direct participant or indirectly through a participant in DTC

·
if the beneficial ownership interest in the Notes is held (a) with any person in a joint tenancy with right of survivorship, (b) with the

deceased beneficial owner's spouse in tenancy by the entirety, tenancy in common, as community property or in any other joint ownership
arrangement, or (c) as tenant in common with a person other than his or her spouse, evidence satisfactory to Barclays Bank PLC of such
relationship;

·
if the beneficial ownership interest in the Notes is held by a nominee or trustee of, custodian for or other person in a similar capacity to the

deceased beneficial owner, a certificate satisfactory to Barclays Bank PLC from such nominee, trustee, custodian or similar person
attesting to the deceased's current beneficial ownership in such Notes;

·
tax certifications and such other instruments or documents that the Barclays Bank PLC may reasonably require in order to establish the

validity of the beneficial ownership of the Notes and the claimant's entitlement to payment; and

·
any additional information Barclays Bank PLC may reasonably require to evidence satisfaction of any conditions to the exercise of the

Survivor's Option or to document beneficial ownership or authority to make the election and to cause the repayment of the Notes.

PS-4
7 of 17
3/27/2013 3:00 PM


http://www.sec.gov/Archives/edgar/data/312070/000110465913024815/...

In turn, the Financial Institution wil provide to the trustee, and the trustee wil forward to Barclays Bank PLC, the Survivor's Option Documentation.
Upon acceptance by Barclays Bank PLC, the trustee wil be responsible for disbursing any payments to DTC, pursuant to exercise of the Survivor's
Option, to be forwarded by DTC to the appropriate Financial Institution for disbursement to the Authorized Representative.

In the event that a valid exercise of a Survivor's Option is not accepted, or is not ful y accepted, by us in a particular calendar year due to the
application of the Put Limitations, we wil forward to the trustee a Survivor's Option Reaffirmation Form, which is attached hereto as Appendix B (a
"Survivor's Option Reaffirmation Form"), relating to the relevant Notes, which shal include the identification number assigned by the trustee to each
Survivor's Option request upon receipt by it that relates to the relevant Notes and the request to exercise the Survivor's Option, or such other code
used by the trustee to track and identify Survivor's Option requests. We intend to deliver to the trustee such Survivor's Option Reaffirmation Form by
January 15 of each succeeding calendar year until the ful amount of the Survivor's Option has been paid (each such year shall be referred to in this
section as a "Succeeding Year"). The trustee wil in turn forward the Survivor's Option Reaffirmation Form to the relevant Financial Institution on or
before February 5 of each Succeeding Year.

Al tendered Notes that are not accepted in any calendar year due to the application of the Put Limitations wil be considered to be tendered in the
fol owing calendar year only if an Authorized Representative and the relevant Financial Institution reaffirm the intent to exercise the Survivor's Option by
marking the appropriate box in the Survivor's Option Reaffirmation Form and returning a completed copy thereof along with a copy of the previously
submitted Survivor's Option Documentation to the trustee within 10 business days fol owing the delivery by the trustee of the Survivor's Option
Reaffirmation Form. The Financial Institution wil provide to the trustee, and the trustee wil forward to Barclays Bank PLC, the Survivor's Option
Reaffirmation Form along with a copy of the previously submitted Survivor's Option Documentation. Upon acceptance by Barclays Bank PLC, the
trustee wil be responsible for disbursing any payments to DTC, pursuant to the exercise of the Survivor's Option, to be forwarded by DTC to the
appropriate Financial Institution for disbursement to the Authorized Representative.

If the Financial Institution (on behalf of the Authorized Representative) marks the box in the Survivor's Option Reaffirmation Form indicating an intent to
withdraw an election to exercise the Survivor's Option, the request to exercise the Survivor's Option wil be withdrawn. In addition, if a completed
Survivor's Option Reaffirmation Form is not returned to the trustee within 10 business days fol owing its delivery by the trustee, the request to exercise
the Survivor's Option wil be deemed to have been withdrawn.

In the event that a request to exercise a Survivor's Option is withdrawn or deemed to have been withdrawn, a request to exercise the Survivor's Option
may be reinstated only by completion of a new Form of Notice and resubmission of the other Survivor's Option Documentation that is required in
connection with a request to exercise a Survivor's Option pursuant to the paragraphs above. Any such subsequent resubmission wil again be subject
to the conditions for exercise of a Survivor's Option as wel as Put Limitations.

The amount that wil be eligible for repayment pursuant to a valid submission of a Survivor's Option Reaffirmation Form wil be equal to the difference
between the amount specified in the initial request to exercise the Survivor's Option less any portion of that amount actually repaid. No amounts that
are greater or less than such difference may be submitted for repayment pursuant to a Survivor's Option Reaffirmation Form. Amounts accepted for
repayment fol owing a submission of a Survivor's Option Reaffirmation Form wil be repaid, subject to the Put Limitations, on the Survivor's Option
Payment Date that occurs 30 or more calendar days after the date of the acceptance by us of the request for repayment set forth in the Survivor's
Option Reaffirmation Form.

For the avoidance of doubt, a Survivor's Option Reaffirmation Form wil be accepted only if it is executed by a person who would be considered an
Authorized Representative as of the date of the Survivor's Option Reaffirmation Form and by the relevant Financial Institution. Al repayment requests
included in a Survivor's Option Reaffirmation Form wil be subject to the Put Limitations.

In respect of the exercise of any Survivor's Option, separate Forms of Notice and Survivor's Option Reaffirmation Forms, as the case may be, are
required to be delivered to the Document Administrator by the Financial Institution for each CUSIP.

During any time in which the Notes are not represented by a global note and are issued in definitive form:

·
al references in this section to participants and DTC, including the DTC's governing rules, regulations and procedures, wil be deemed

inapplicable;

PS-5
8 of 17
3/27/2013 3:00 PM


http://www.sec.gov/Archives/edgar/data/312070/000110465913024815/...

· al determinations that the DTC participants are required to make as described in this section wil be made by Barclays Bank PLC, including,
without limitation, determining whether the applicable decedent is in fact the beneficial owner of the interest in the Notes to be redeemed or is in
fact deceased and whether the representative is duly authorized to request redemption on behalf of the applicable beneficial owner; and

·
al redemption requests, to be effective, must:


·
be delivered by the representative to Barclays Bank PLC and to the trustee;


·
be made by completing the Form of Notice (including al exhibits thereto) or a Survivor's Option Reaffirmation Form, as the case may

be, in accordance with the related instructions; and

·
be accompanied by, if applicable, a properly executed assignment or endorsement, in addition to all documents that are otherwise

required to accompany a redemption request. If the record holder of the Note is a nominee of the deceased beneficial owner, a
certificate or letter from the nominee attesting to the deceased's ownership of a beneficial interest in the Note must also be delivered.

Barclays Bank PLC retains the right to further limit the aggregate principal amount of Notes as to which exercises of the Survivor's Option wil be
accepted from all authorized representatives of deceased beneficial owners and from the authorized representative for any individual deceased
beneficial owner in any one calendar year as described above. Al other questions regarding the eligibility or validity of any exercise of the Survivor's
Option generally wil be determined by Barclays Bank PLC, which determination wil be final and binding on all parties.

Whether you should exercise a Survivor's Option if you meet the eligibility requirements to do so is a decision you wil need to make in consultation with
your investment, legal, accounting, tax and other advisers, after considering al the facts and circumstances of your situation. Another consideration that
you may wish to take into account is the prevailing secondary market prices for the notes, if any, at the time you are considering the exercise of the
Survivor's Option or the submission of a Survivor's Option Reaffirmation Form. In some circumstances, such secondary market prices, if any, may be
greater than the price you would receive upon the exercise of your Survivor's Option. Accordingly, you should contact your advisers to determine the
prevailing secondary market prices of the notes, if any, in order to determine whether to sel the notes to a market participant at such secondary market
prices, if any, or to exercise the Survivor's Option to receive repayment at a price equal to 100% of the principal amount plus accrued and unpaid
interest.

Forms for the exercise of the Survivor's Option are attached hereto and may be obtained from The Bank of New York Mel on, London Branch, One
Canada Square, Canary Wharf, London E 14 5AL, England.

UNITED STATES FEDERAL INCOME TAX TREATMENT

The fol owing discussion supplements the discussion in the prospectus supplement under the heading "Certain U.S. Federal Income Tax Considerations"
and supersedes it to the extent inconsistent therewith. The fol owing discussion (in conjunction with the discussion in the prospectus supplement)
summarizes certain of the material U.S. federal income tax consequences of the purchase, beneficial ownership, and disposition of the Notes.

We intend to treat the Notes as indebtedness for U.S. federal income tax purposes and any reports to the Internal Revenue Service (the "IRS") and
U.S. holders wil be consistent with such treatment, and each holder wil agree to treat the Notes as indebtedness for U.S. federal income tax
purposes. The discussion that fol ows is based on this approach.

Interest paid on the Notes wil be taxable to a U.S. holder as ordinary interest income at the time it accrues or is received in accordance with the U.S.
holder's normal method of accounting for tax purposes. See "Certain U.S. Federal Income Tax Considerations--U.S. Federal Income Tax Treatment of
the Notes as Indebtedness for U.S. Federal Income Tax Purposes--Payments of Interest" in the prospectus supplement.

3.8% Medicare Tax On "Net Investment Income"

U.S. holders that are individuals, estates, and certain trusts are subject to an additional 3.8% tax on all or a portion of their "net investment income,"
which may include the interest payments and any gain realized with respect to the Notes, to the extent of their net investment income that, when added
to their other modified adjusted gross income, exceeds $200,000 for an unmarried individual, $250,000 for a married taxpayer filing a joint return (or a
surviving spouse), or $125,000 for a married individual filing a separate return. U.S. holders should consult their advisors with respect to the 3.8%
Medicare tax.

PS-6
9 of 17
3/27/2013 3:00 PM


http://www.sec.gov/Archives/edgar/data/312070/000110465913024815/...

Information Reporting

Holders that are individuals (and, to the extent provided in future regulations, entities) may be may be required to disclose information about their Notes
on IRS Form 8938--"Statement of Specified Foreign Financial Assets" if the aggregate value of their Notes and their other "specified foreign financial
assets" exceeds $50,000. Significant penalties can apply if a holder fails to disclose its specified foreign financial assets. We urge you to consult your
tax advisor with respect to this and other reporting obligations with respect to your Notes.

Non-U.S. Holders

Barclays currently does not withhold on interest payments to non-U.S. holders in respect of instruments such as the Notes. However, if Barclays
determines that there is a material risk that it wil be required to withhold on any such payments, Barclays may withhold on such payments at a 30%
rate, unless non-U.S. holders have provided to Barclays an appropriate and valid Internal Revenue Service Form W-8. In addition, non-U.S. holders wil
be subject to the general rules regarding information reporting and backup withholding as described under the heading "Certain U.S. Federal Income
Tax Considerations--Information Reporting and Backup Withholding" in the accompanying prospectus supplement.

PROSPECTIVE PURCHASERS SHOULD CONSULT THEIR TAX ADVISORS AS TO THE FEDERAL, STATE, LOCAL, AND OTHER TAX
CONSEQUENCES TO THEM OF THE PURCHASE, OWNERSHIP AND DISPOSITION OF NOTES.

CERTAIN EMPLOYEE RETIREMENT INCOME SECURITY ACT CONSIDERATIONS

Your purchase of a Note in an Individual Retirement Account (an "IRA"), wil be deemed to be a representation and warranty by you, as a fiduciary of
the IRA and also on behalf of the IRA, that (i) neither the issuer, the placement agent nor any of their respective affiliates has or exercises any
discretionary authority or control or acts in a fiduciary capacity with respect to the IRA assets used to purchase the Note or renders investment advice
(within the meaning of Section 3(21)(A)(ii) of the Employee Retirement Income Security Act ("ERISA")) with respect to any such IRA assets and (ii) in
connection with the purchase of the Note, the IRA wil pay no more than "adequate consideration" (within the meaning of Section 408(b)(17) of ERISA)
and in connection with any redemption of the Note pursuant to its terms wil receive at least adequate consideration, and, in making the foregoing
representations and warranties, you have (x) applied sound business principles in determining whether fair market value wil be paid, and (y) made such
determination acting in good faith.

For additional ERISA considerations, see "Employee Retirement Income Security Act" in the prospectus supplement.

SUPPLEMENTAL PLAN OF DISTRIBUTION

We have agreed to sel to Barclays Capital Inc. (the "Agent"), and the Agent has agreed to purchase from us, the principal amount of the Notes, and at
the price, specified on the cover of this pricing supplement. The Agent is committed to take and pay for al of the Notes, if any are taken.

PS-7
10 of 17
3/27/2013 3:00 PM